唾液巨噬细胞迁移抑制因子水平与原发性干燥综合征的相关性研究

Abstract
Figure/Table
References (21)
Related Citation (13)

Download: PDF (632 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objectives To detect salivary macrophage migration inhibitory factor (MIF) level in patients with primary Sjögren′s syndrome (pSS) and investigate the correlation between MIF level and disease activity. Methods The pSS patients diagnosed in Beijing University of Chinese Medicine Third Affiliated Hospital (hereinafter referred to as "our hospital") from October 2009 to October 2018 were enrolled as pSS group (96 cases); the other age- and sex- matched healthy people were included as control group (70 people) during the same period of our hospital. The disease activity of patients with pSS were evaluated, and the salivary MIF level of each group were compared. The relationship between salivary MIF level and the incidence of pSS was evaluated, while the correlation between saliva MIF levels and EULAR Sjogren′s syndrome disease activity index (ESSDAI) were analyzed. Results The salivary MIF level in the pSS group was significantly higher than that in the control group, and the differences were highly statistically significant (P ＜ 0.01). Salivary MIF level was the independent risk factors for pSS [OR（95%CI）=1.996（1.339-2.977），P ＜ 0.01]. Salivary MIF level was positively correlated with ESSDAI (r = 0.276，P ＜ 0.01). Conclusion Salivary MIF level is expected to be an important biomarkers for predicting the development of pSS.

Key words： Primary Sjögren′s syndrome Macrophage migration inhibitory factor Salivary Biomarker

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIANG Lu WANG Yumeng PEI Tingting

Cite this article:

QIANG Lu WANG Yumeng PEI Tingting. The correlation between salivary macrophage migration inhibitory factor levels and primary Sjögren′s syndrome[J]. 中国医药导报, 2019, 16(28): 103-105,117.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I28/103

[1] Goules AV，Tzioufas AG. Lymphomagenesis in Sjögren′s syndrome：Predictive biomarkers towards precision medici-ne [J]. Autoimmun Rev，2019，18（2）：137-143.
[2] 侯佳奇，薛鸾.原发性干燥综合征发病机制概述[J].现代免疫学，2019，39（1）：58-63.
[3] McCoy SS，Baer AN. Neurological Complications of Sjögren′s Syndrome：Diagnosis and Management [J]. Curr Treatm Opt Rheumatol，2017，3（4）：275-288.
[4] Carubbi F，Alunno A，Cipriani P，et al. Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren′s syndrome minor salivary glands [J]. PLoS One，2019，14（1）：e0211142.
[5] Nocturne G，Mariette X. Advances in understanding the pathogenesis of primary Sjögren′s syndrome [J]. Nat Rev Rheumatol，2013，9（9）：544-556.
[6] Yachoui R，Leon C，Sitwala K，et al. Pulmonary MALT Lymphoma in Patients with Sjögren′s Syndrome [J]. Clin Med Res，2017，15（1/2）：6-12.
[7] 张先瑞，方美云.干燥综合征合并黏膜相关淋巴瘤漏诊分析并文献复习[J].现代医学，2018，46（9）：1065-1068.
[8] Rosado SN，Silveira V，Reis AI，et al. Catatonia and Psychosis as Manifestations of Primary Sjögren′s Syndrome [J]. Eur J Case Rep Intern Med，2018，5（6）：000855.
[9] Bae SC，Lee YH. Circulating macrophage migration inhibitory factor levels and its polymorphisms in systemic lupus erythematosus：A meta-analysis [J]. Cell Mol Biol（Noisy-le-grand），2017，63（10）：74-79.
[10] Bae SC，Lee YH. Associations between circulating mac-rophage migration inhibitory factor（MIF）levels and rheumatoid arthritis，and between MIF gene polymorphisms and disease susceptibility：a meta-analysis [J]. Postgrad Med J，2018，94（1108）：109-115.
[11] 杜向荣，宋守君，薛海波.巨噬细胞移动抑制因子在自身免疫性疾病发病中作用的研究进展[J].山东医药，2018，58（16）：110-112.
[12] 王艳，张亚妹，王维伟，等.巨噬细胞迁移抑制因子在多发性肌炎/皮肌炎患者中的意义[J].检验医学与临床，2018，15（9）：1245-1248.
[13] Günther S，Fagone P，Jalce G，et al. Role of MIF and D-DT in immune-inflammatory，autoimmune，and chronic respiratory diseases：from pathogenic factors to therapeutic targets [J]. Drug Discov Today，2019，24（2）：428-439.
[14] Vitali C，Bombardieri S，Jonsson R，et al. Classification criteria for Sjögren′s syndrome：a revised version of the European criteria proposed by the American-European Consensus Group [J]. Ann Rheum Dis，2002，61（6）：554-558.
[15] 强璐，王雨萌，徐林.唾液中IL-8的水平与复发性阿弗他溃疡的相关性[J].山西医科大学学报，2018，49（11）：1394-1396.
[16] Seror R，Bootsma H，Saraux A，et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren′s syndrome with EULAR primary Sjögren′s syndrome disease activity（ESSDAI）and patient-reported indexes（ESSPRI） [J]. Ann Rheum Dis，2016， 75（2）：382-389.
[17] Leyton-Jaimes MF，Kahn J，Israelson A. Macrophage migration inhibitory factor：A multifaceted cytokine implicated in multiple neurological diseases [J]. Exp Neurol，2018，301（Pt B）：83-91.
[18] Willeke P，Gaubitz M，Schotte H，et al. Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren′s syndrome [J]. Arthritis Res Ther，2007，9（2）：R43.
[19] Vincent FB，Lang T，Kandane-Rathnayake R，et al. Serum and urinary macrophage migration inhibitory factor（MIF）in primary Sjögren′s syndrome [J]. Joint Bone Spine，2019，86（3）：393-395.
[20] Rijvers L，Melief MJ，van der Vuurst de Vries RM，et al. The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis [J]. Eur J Immunol，2018，48（11）：1861-1871.
[21] Baer AN，Medrano L，McAdams-DeMarco M，et al. Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren′s Syndrome：Analysis of the Sjögren′s International Collaborative Clinical Alliance Cohort [J]. Arthritis Care Res（Hoboken），2016，68（10）：1554-1559.